References
- Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics – 2013 update: a report from the American Heart Association. Circulation 2013;127:e6-245
- Mantha S, Cabral K, Ansell J. New avenues for anticoagulation in atrial fibrillation. Clin Pharmacol Ther 2013;93:68-77
- Palareti G, Cosmi B. Bleeding with anticoagulation therapy – who is at risk, and how best to identify such patients. Thromb Haemost 2009;102:268-78
- Hankey GJ, Eikelboom JW. Novel oral anticoagulants for atrial fibrillation. Curr Atheroscler Rep 2013;15:344
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
- Clayville LR, Anderson KV, Miller SA, et al. New options in anticoagulation for the prevention of venous thromboembolism and stroke. P T 2011;36:86-99
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883-91
- Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981-92
- Cohen J. Statistical power analysis for the behavioral sciences. Toronto: Academic Press Inc., 1977:19-74
- Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001;54:387-98
- Austin P. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Comm Stat Simulat Comput 2009;38:1228-34
- Becattini C, Vedovati MC, Agnelli G. Old and new anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature. Thromb Res 2012;129:392-400
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67
- Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:160-98S
- Choudhry NK, Fischer MA, Avorn J, et al. The implications of therapeutic complexity on adherence to cardiovascular medications. Arch Intern Med 2011;171:814-22
- Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29:675-90
- Zalesak M, Siu K, Francis K, et al. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin. Circ Cardiovasc Qual Outcomes 2013;6:567-74
- Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010;363:2499-510